Phase II trial shows new CAR-T therapy is viable in acute lymphoblastic leukemia patients

Written by Harriet Wall

In a new Phase II ‘ZUMA-3’ study from researchers at Kite, a Gilead Company (CA, USA), a novel chimeric antigen receptor (CAR) T-cell therapy known as Tecartus has been evaluated in patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), which is an aggressive form of blood cancer. The results were recently published in the journal, The Lancet, and presented at the American Society of Clinical Oncology (ASCO) Annual Meeting (4–8 June 2021; virtual). Treatment options for patients with relapsed or refractory B-precursor ALL are limited, and there is an immense need for novel therapies. Tecartus can use...

To view this content, please register now for access

It's completely free